Utilize este identificador para referenciar este registo: https://hdl.handle.net/10316/106804
Título: Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease
Autor: Baldeiras, Inês 
Santana, Isabel 
Leitão, Maria João 
Vieira, Daniela 
Duro, Diana
Mroczko, Barbara
Kornhuber, Johannes
Lewczuk, Piotr
Palavras-chave: Alzheimer’s disease; Mild cognitive impairment—progression; Cerebrospinal fluid; Biomarker
Data: 5-Jan-2019
Editora: Springer Nature
Projeto: PD/BD/135108/2017 
SFRH/BD/52289/2013 
CENTRO-01- 0145-FEDER-000008:BrainHealth 2020 
Título da revista, periódico, livro ou evento: Alzheimer's Research and Therapy
Volume: 11
Número: 1
Resumo: Background: The previously described and validated Erlangen Score (ES) algorithm enables interpretation of the cerebrospinal fluid (CSF) biomarkers of Alzheimer’s disease (AD), ordering them on an ordinal scale: from neurochemically normal (ES = 0) through improbable AD (ES = 1), possible AD (ES = 2 or 3), to probable AD (ES = 4). Here we assess the accuracy of the ES in predicting hazards of progression from the mild cognitive impairment (MCI) stage of AD to the dementia stage of the disease (Alzheimer’s disease dementia (ADD)) in a novel, single-center cohort. Methods: Baseline CSF biomarkers (amyloid beta (Aβ) 1–42, Aβ42/40, Tau, and pTau181), interpreted according to the ES, were used to estimate time to progression from the MCI stage of AD to ADD, conditional on age, gender, APOE ε4 genotype, and Mini Mental State Examination score in 144 MCI subjects, using the Extended Cox Model; the subjects were followed-up until they developed dementia or until they had been cognitively stable for at least 2 years. In addition, ES distributions were studied in 168 ADD cases and 66 neurologic controls. Further, we stratified MCI patients into those who progressed to ADD faster (within 3 years, n = 47) and those who progressed slower (n = 74). Results: The distributions of the ES categories across the four diagnostic groups (Controls, MCI-Stable, MCI-AD, and ADD) were highly significantly different (Kruskal–Wallis χ2(df = 3) = 151.4, p < 0.001), with significant contrasts between each pair (p < 0.005), except between the ADD and the MCI-AD groups (p = 1.0). MCI patients with ES = 2 or 3 had 6–8 times higher hazards to progress to ADD compared to patients with ES = 0 or 1 in the first 3 follow-up years, and then their hazards decreased to those of the group with ES = 0 or 1. Patients with ES = 4 had hazards 8–12 times higher compared to the ES = 0 or 1 group. Faster progressors with ES = 2 or 3 had, in comparison to slower progressors, significantly lower Aβ1–42, Aβ1–40, and Aβ42/40, but comparable Tau and pTau181. A highly significant difference of the ES distributions between these two groups was observed (p < 0.001). Conclusions: Our current results reconfirm and extend the conclusions of the previously published report that the Erlangen Score is a useful tool facilitating interpretation of a complex pattern of the CSF AD biomarkers.
URI: https://hdl.handle.net/10316/106804
ISSN: 1758-9193
DOI: 10.1186/s13195-018-0456-x
Direitos: openAccess
Aparece nas coleções:I&D CNC - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais

Mostrar registo em formato completo

Citações SCOPUSTM   

20
Visto em 2/set/2024

Citações WEB OF SCIENCETM

16
Visto em 2/jul/2024

Visualizações de página

79
Visto em 11/set/2024

Downloads

90
Visto em 11/set/2024

Google ScholarTM

Verificar

Altmetric

Altmetric


Este registo está protegido por Licença Creative Commons Creative Commons